Clinical trial
Different Doses of Naronapride vs. Placebo in Gastroparesis
NCT05621811
Study timeline
Study start (actual)2023-01-03Date precision: day
Registry last updated2026-10-07
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Gastroparesisunresolved
Interventions
NaronaprideDRUG
PlaceboDRUG
Sponsors & collaborators
Dr. Falk Pharma GmbHlead sponsor
Mapped research locations
MiamiFlorida, United States2FlintMichigan, United States2New YorkNew York, United States1PhiladelphiaPennsylvania, United States1NashvilleTennessee, United States1ClevelandOhio, United States1LeuvenBelgium1Kansas CityKansas, United States1TulsaOklahoma, United States1HollywoodFlorida, United States1ClearwaterFlorida, United States1TopekaKansas, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05621811 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.